皇冠足彩APP

LUNA Company

Active pharmaceutical ingredients Sales of products are limited to those allowed by Chapter VII PLPRC 63, the above includes Research and development quantities.

Product >> LUNA RD

Tofacitinib

Product Name: Tofacitinib
Synonyms: 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; CP 690550;3-Piperidinamine, 1-(cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo(2,3-D)pyrimidin-4-yl-, (3R,4R)-; CP-690550(Tasocitinib,CP690550); CP 690550(Tasocitinib); Tasocitinib; Tasocitinib (CP 690550)
CAS: 477600-75-2
MF: C16H20N6O
MW: 312.3696
Mol File: 477600-75-2.mol
USE: Tofacitinib is a drug of the janus kinase (JAK) inhibitor class, discovered and developed by Pfizer. It is currently approved for the treatment of rheumatoid arthritis (RA) in the United States and Russia, and is being studied for treatment of psoriasis, inflammatory bowel disease, and other immunological diseases, as well as for the prevention of organ transplant rejection. Tofacitinib was not approved by the European regulatory agencies because of concerns over efficacy and safety.